If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor Prostate Cancer advisory service, Decision Resources is offering an exclusive analyst call entitled Rising Out of the Crowded Prostate Cancer Pipeline: Which New and Emerging Agents Will Become Market Leaders in 2019? Because this presentation features major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Owing to multiple first-in-class entries of emerging therapies, the prostate cancer drug market will grow to more than $8.4 billion in 2019. The primary driver of market growth will be the novel therapeutic vaccine, Dendreon’s Provenge. Also contributing to market expansion will be the recently approved next-generation taxane, Sanofi-Aventis’s Jevtana. This presentation will also highlight emerging therapies that have recently entered Phase III clinical development, such as OncoGenex/Teva’s custirsen. Compared with many oncology indications, the prostate cancer drug market is particularly dynamic and has a rich late-stage emerging pipeline with 15 emerging therapies currently pre-registered or in Phase III clinical development. Using 2009 as a base year, our Prostate Cancer advisory service findings have been updated with recently released data and revised epidemiological assumptions. The service provides thought-leaders’ opinions on key clinical unmet needs, our assumptions behind current clinical practice and emerging trends in disease management. This 15-minute analyst call, presented by Analyst Andrew Merron, Ph.D., will answer the following questions:
Dr. Merron will conduct a live Q & A session after the presentation. Registration Rising Out of the Crowded Prostate Cancer Pipeline: Which New and Emerging Agents Will Become Market Leaders in 2019? July 8, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Andrew Merron, Ph.D., is a senior oncology analyst at Decision Resources. Dr Merron’s research interests and areas of expertise cover hematological malignancies (including lymphoma, leukemia and myeloma) and prostate cancer. Dr. Merron received his Ph.D. in molecular oncology from the University of London. His doctorate focused on in vivo molecular imaging of cancer gene therapies, specifically oncolytic adenoviruses. Prior to obtaining his Ph.D., he earned his B.Sc. in biochemistry from the University of Bath.